Clinical Scorecard: Prognostic Role of Atrial Functional Mitral Regurgitation in Patients with Heart Failure with Preserved Ejection Fraction and End-Stage Renal Disease
At a Glance
Category
Detail
Condition
Atrial Functional Mitral Regurgitation (AFMR)
Key Mechanisms
Mitral annular expansion and left atrial hypertrophy leading to compromised coaptation of mitral valve leaflets.
Target Population
Individuals with Heart Failure with Preserved Ejection Fraction (HFpEF) and End-Stage Renal Disease (ESRD) receiving hemodialysis.
Care Setting
Hemodialysis centers.
Key Highlights
AFMR is associated with increased all-cause mortality (25.6% vs. 12.3%).
AFMR is an independent predictor of all-cause mortality (HR: 2.456).
Even mild AFMR is linked to elevated mortality risk (HR: 2.155).
Moderate to severe AFMR correlates with significant cardiac function decline.
Plasma ANP concentrations may serve as a biomarker for AFMR.
Guideline-Based Recommendations
Diagnosis
Utilize echocardiography to assess mitral valve function and left atrial size.
Management
Prompt recognition and treatment of AFMR in patients with HFpEF and ESRD.
Monitoring & Follow-up
Regular assessment of cardiac function and ANP levels in patients with AFMR.
Risks
Increased risk of all-cause mortality and cardiac function decline associated with AFMR.
Patient & Prescribing Data
Patients with HFpEF and ESRD undergoing hemodialysis.
Limited treatment options available; focus on management of underlying heart failure and renal function.
Clinical Best Practices
Monitor for signs of AFMR in patients with HFpEF and ESRD.
Consider ANP levels as a potential diagnostic tool for AFMR.
Implement strategies to manage volume status and cardiac function.
